Immutep (ASX:IMM) reported a 60.8% response rate and 90.2% disease control rate in the Insight-003 trial, according to a Thursday filing with the Australian bourse.

The trial is evaluating eftilagimod alpha in combination with anti-PD-1 therapy, Keytruda, and doublet chemotherapy as first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer, the filing said.

The overall response rate in all evaluable patients showed a "significant" improvement compared with historical control from a registrational trial of anti-PD-1 and doublet chemotherapy in non-squamous non-small cell lung cancer, according to the filing.